Tratamiento antiagregante plaquetario personalizado

Paul A. Gurbel; Rahil Rafeedheen; Udaya S. Tantry

doi:10.1016/j.recesp.2014.01.013

Tratamiento antiagregante plaquetario personalizado

Translated title of the contribution: Personalized antiplatelet therapy

Paul A. Gurbel, Rahil Rafeedheen, Udaya S. Tantry

School of Medicine

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

It is well established that high on-treatment platelet reactivity to adenosine diphosphate during clopidogrel therapy is an independent risk factor for ischemic event occurrences in a postpercutaneous coronary intervention patients. However, the precise role of platelet function testing remains debated. Platelet function testing to ensure optimal platelet inhibition has been recommended by some authorities to improve outcomes in patients treated with clopidogrel. Recent prospective, randomized trials of personalized antiplatelet therapy have failed to demonstrate a benefit of platelet function testing in improving outcomes. In this review article, we discuss the mechanisms responsible for clopidogrel nonreponsiveness, recent trials of platelet function testing, and other new developments in the field of personalized antiplatelet therapy.

Translated title of the contribution	Personalized antiplatelet therapy
Original language	Spanish
Pages (from-to)	480-487
Number of pages	8
Journal	Revista Espanola de Cardiologia
Volume	67
Issue number	6
DOIs	https://doi.org/10.1016/j.recesp.2014.01.013
State	Published - Jun 2014

Keywords

Genotyping
Personalized antiplatelet therapy
Platelet function testing
Thrombosis

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.recesp.2014.01.013

Cite this

@article{bffb86a80e8d4fa9909c2d0e9ba443c0,

title = "Tratamiento antiagregante plaquetario personalizado",

abstract = "It is well established that high on-treatment platelet reactivity to adenosine diphosphate during clopidogrel therapy is an independent risk factor for ischemic event occurrences in a postpercutaneous coronary intervention patients. However, the precise role of platelet function testing remains debated. Platelet function testing to ensure optimal platelet inhibition has been recommended by some authorities to improve outcomes in patients treated with clopidogrel. Recent prospective, randomized trials of personalized antiplatelet therapy have failed to demonstrate a benefit of platelet function testing in improving outcomes. In this review article, we discuss the mechanisms responsible for clopidogrel nonreponsiveness, recent trials of platelet function testing, and other new developments in the field of personalized antiplatelet therapy.",

keywords = "Genotyping, Personalized antiplatelet therapy, Platelet function testing, Thrombosis",

author = "Gurbel, {Paul A.} and Rahil Rafeedheen and Tantry, {Udaya S.}",

year = "2014",

month = jun,

doi = "10.1016/j.recesp.2014.01.013",

language = "Spanish",

volume = "67",

pages = "480--487",

journal = "Revista Espanola de Cardiologia",

issn = "0300-8932",

publisher = "Ediciones Doyma, S.L.",

number = "6",

}

TY - JOUR

T1 - Tratamiento antiagregante plaquetario personalizado

AU - Gurbel, Paul A.

AU - Rafeedheen, Rahil

AU - Tantry, Udaya S.

PY - 2014/6

Y1 - 2014/6

N2 - It is well established that high on-treatment platelet reactivity to adenosine diphosphate during clopidogrel therapy is an independent risk factor for ischemic event occurrences in a postpercutaneous coronary intervention patients. However, the precise role of platelet function testing remains debated. Platelet function testing to ensure optimal platelet inhibition has been recommended by some authorities to improve outcomes in patients treated with clopidogrel. Recent prospective, randomized trials of personalized antiplatelet therapy have failed to demonstrate a benefit of platelet function testing in improving outcomes. In this review article, we discuss the mechanisms responsible for clopidogrel nonreponsiveness, recent trials of platelet function testing, and other new developments in the field of personalized antiplatelet therapy.

AB - It is well established that high on-treatment platelet reactivity to adenosine diphosphate during clopidogrel therapy is an independent risk factor for ischemic event occurrences in a postpercutaneous coronary intervention patients. However, the precise role of platelet function testing remains debated. Platelet function testing to ensure optimal platelet inhibition has been recommended by some authorities to improve outcomes in patients treated with clopidogrel. Recent prospective, randomized trials of personalized antiplatelet therapy have failed to demonstrate a benefit of platelet function testing in improving outcomes. In this review article, we discuss the mechanisms responsible for clopidogrel nonreponsiveness, recent trials of platelet function testing, and other new developments in the field of personalized antiplatelet therapy.

KW - Genotyping

KW - Personalized antiplatelet therapy

KW - Platelet function testing

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84901621062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901621062&partnerID=8YFLogxK

U2 - 10.1016/j.recesp.2014.01.013

DO - 10.1016/j.recesp.2014.01.013

M3 - Article

AN - SCOPUS:84901621062

SN - 0300-8932

VL - 67

SP - 480

EP - 487

JO - Revista Espanola de Cardiologia

JF - Revista Espanola de Cardiologia

IS - 6

ER -

Tratamiento antiagregante plaquetario personalizado

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this